Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


DxS grants ETS additional license to provide diagnostics for fuel ethanol testing


Manchester, 3 November 2008 DxS Ltd, a personalised medicine company and leaders in the provision of companion diagnostics, has granted ETS Laboratories, the world leader for innovation in wine analysis, an additional license to use DxS’ Scorpions technology to test for the presence of organisms, which could contaminate biofuel fermentations.

This new license is an addition to an existing license agreement under which ETS uses Scorpions to detect organisms which could cause spoilage in wine or juice. While DxS’ real-time PCR Scorpions technology can be utilised in a wide range of genetic diagnostic applications, it can be used for a variety of other purposes including environmental analysis, food testing and biothreat detection, due to its high sensitivity and fast reaction times.

Dr Stephen Little, CEO of DxS said: “This new agreement shows just how effective Scorpions is, not just as an in vitro diagnostic, but also for other uses where testing needs to be done quickly and with a high degree of sensitivity. We are very pleased to be able to be able to provide this additional license, which allows ETS to maintain its position as the world leader in the detection of contaminating organisms.”

Gordon Burns, President of ETS Laboratories added: “Scorpions has proven itself to be an excellent technology allowing ETS to quickly and efficiently test wines for potentially damaging contaminants and we know it will be equally effective for monitoring biofuel fermentations.”

Financial terms were not disclosed.

-ends-

For further information, please contact:


Sue Charles, Tony Stephenson, Dr John McIntyre
College Hill Life Sciences
+44 (0)20 7866 7864
DxS@collegehill.com


Notes to Editors

DxS is a personalised medicine company providing products, technology and services to the healthcare industry to enable the delivery of safe and effective medicines. The Company has also established itself as a leader in the provision of companion diagnostics to the personalised cancer medicine market.

DxS has a range of products including cancer mutation assays and kits, molecular diagnostic technologies and genetic analysis services. Its TheraScreen® range of CE-marked kits can identify genetic tumour mutations affecting how patients respond to cancer therapies, enabling doctors and drug companies to provide the treatment most likely to benefit patients. DxS produce two clinical diagnostic kits, K-RAS, and EGFR-29. The K-RAS assay has been chosen as the companion diagnostic for Amgen’s colorectal cancer therapy Vectibix®. DxS has an exclusive global distribution agreement with Roche Molecular Systems for the distribution of the TheraScreen K-RAS Mutation Test and TheraScreen EGFR 29 Mutation Test.

DxS’ real-time PCR technology, Scorpions® utilises its speed and sensitivity and underpins the products and services. This class-leading technology is also available for licence to diagnostic companies, for research, applied and other applications.

DxS is a private, venture capital backed company operating from Manchester’s Technology Quarter within the UK.

For further information please visit www.dxsdiagnostics.com


Publisher Contact Information:

College Hill Life Sciences
+44 (0)20 7866 7864
DxS@collegehill.com

Company profile of DxS Ltd (acquired by Qiagen)
Past press releases of DxS Ltd (acquired by Qiagen).

Data


26,008
Tech investments
From our Online Data Service
16,823
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Aug 19€7.0MAgriculture related
Aug 19€9.0MInternet commerce
Aug 19€10.0ME-Commerce
Aug 19€63.0MBusiness applications
Aug 16€16.0ME-Commerce
Aug 16€6.0MBusiness applications
Aug 15€20.0MGames

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.